Download PDF
Hamostaseologie 2015; 35(04): 364-371
DOI: 10.5482/HAMO-15-06-0019
Review
Schattauer GmbH

Turoctocog alfa (recombinant factor VIII)

Manufacturing, characteristics and clinical trial resultsTuroctocog alfa (rekombinanter Faktor VIII)Herstellung, Eigenschaften und Ergebnisse klinischer Versuche
A. Tiede
1   Department of Haematology, Haemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Germany
,
R. Klamroth
2   Centre for Internal Medicine, Angiology, Haemostaseology and Pulmonology, Haemophilia Centre / Coagulation Consultation, Vivantes Klinikum im Friedrichshain, Berlin, Germany
,
J. Oldenburg
3   Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Germany
› Author AffiliationsWriting assistance to the authors during the preparation of this manuscript was provided by Dr. Detlev Janssen, Med-i-Scene Concept GmbH, 91085 Weisendorf, in compliance with international guidelines for good publication practice, and supported by Novo Nordisk Pharma GmbH, 55127 Mainz, Germany.
Further Information

Publication History

received: 15 June 2015

accepted in revised form: 27 July 2015

Publication Date:
28 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Turoctocog alfa (NovoEight®) is a new recombinant factor VIII (rFVIII) with a truncated B domain and a high degree of tyrosine sulphation, similar to plasma-derived FVIII products. The manufacturing process includes double nanofiltration with a 20-nm pore size and immunoaffinity chromatography with monoclonal F25 anti-FVIII antibodies. Treatment with turoctocog alfa can be monitored with both one-stage and chromogenic substrate assays without a product-specific laboratory standard. In total, 213 previouslytreated patients with severe haemophilia A participated in the pivotal part of the clinical trial programme guardianTM. The median annualised bleeding rate during turoctocog alfa prophylaxis was 3.7 and 3.0 in adolescents/adults and children, respectively, with marked differences between participating countries. The success rate for the treatment of breakthrough bleeds was 85% (adults/ adolescents) and 94% (children). A total of 41 surgical procedures (15 major, 26 minor) were performed in 33 patients, with a successful haemostatic response reported in all cases. No patient developed confirmed inhibitors in any of the trials.

Zusammenfassung

Turoctocog alfa (NovoEight®) ist einer neuer rekombinanter Faktor VIII (rFVIII) mit einer verkürzten B-Domäne und einem hohen Grad an Tyrosin-Sulfatierung, ähnlich wie bei plasmatischen FVIII-Produkten. Der Herstellungsprozess umfasst doppelte Nanofiltration (Porengröße 20 nm) und Immunaffinitätschromatographie mit monoklonalen F25-antiFVIII-Antikörpern. Die Behandlung mit Turoctog alfa kann mittels Einstufentest oder chromogenem Substrattest ohne produktspefizische Kalibratoren erfolgen. Am guardianTM Studienprogramm nahmen insgesamt 213 vorbehandelte Patienten mit schwerer Hämophilie A teil. Die mediane Blutungsrate betrug unter Prophylaxe mit Turoctog alfa 3,7 (Erwachsene) bzw. 3,0 (Kinder) Blutungen pro Patient und Jahr, wobei große Unterschiede zwischen den Ländern beobachtet wurden. Die Erfolgsrate in der Behandlung von Durchbruchsblutungen unter Prophylaxe betrug 85% (Erwachsene) bzw. 94 % (Kinder). 41 operative Eingriffe (15 große und 26 kleine) wurden bei 33 Patienten durchgeführt. In allen Fällen war die Substitution hämostyptisch erfolgreich. In keiner der Studien entwickelte ein Patient einen Hemmkörper.

Keywords

Factor VIII - haemophilia A - NovoEight™ - turoctocog alfa

Schlüsselwörter

Faktor VIII - Hämophilie A - NovoEight™ - Turoctocog alfa
 

  • References

  • 1 Kingdon HS, Lundblad RL. An adventure in biotechnology: the development of haemophilia A therapeutics -from whole-blood transfusion to recombinant DNA to gene therapy. Biotechnol Appl Biochem 2002; 35: 141-148.
    CrossrefPubMedGoogle Scholar
  • 2 Christiansen ML, Balling KW, Persson E. et al. Functional characteristics of N8, a new recombinant FVIII. Haemophilia 2010; 16: 878-887.
    CrossrefPubMedGoogle Scholar
  • 3 Martinowitz U, Bjerre J, Brand B. et al. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATEâ)-an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia 2011; 17: 854-859.
    CrossrefPubMedGoogle Scholar
  • 4 Kelley B, Jankowski M, Booth J. An improved manufacturing process for Xyntha/ReFacto AF. Haemophilia 2010; 16: 717-725.
    CrossrefPubMedGoogle Scholar
  • 5 NovoEight® Prescribing Information. US Food and Drug Administration. www.fda.gov/downloads/Bi logicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM371094.pdf (accessed January 17, 2014).
    PubMedGoogle Scholar
  • 6 EMA Summary of EPAR for the public. NovoEight. 2013
    PubMedGoogle Scholar
  • 7 Swissmedic. NovoEight®, Injektionspräparat (Turoctocogum alfa). 4-9-2014.
    PubMedGoogle Scholar
  • 8 Australian Government Department of Health. Review of Australia’s plasma fractionation arrangements. www health gov au/internet/main/ publishing nsf/Content/ B3B4E1D741764DD2CA257BF000193A6F/$File/plasma_FINAL%20as%20at%2030%20November%202006 pdf (accessed May 6, 2015).
    PubMedGoogle Scholar
  • 9 World Federation of Hemophilia. Report on the annual global survey 2012. 2013
    PubMed
  • 10 Hermans C, Brackmann HH, Schinco P, Auerswald G. The case for wider use of recombinant factor VIII concentrates. Crit Rev Oncol Hematol 2012; 83: 11-20.
    CrossrefPubMedGoogle Scholar
  • 11 Di Minno G, Canaro M, Ironside JW. et al. Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice. Haematologica 2013; 98: 1495-1498.
    CrossrefPubMedGoogle Scholar
  • 12 Burger R, Offergeld R. Sitzung des Arbeitskreises Blut vom 27. Juni. 2012 www.rki.de/DE/Content/ Kommissionen/AK_Blut/Sitzungsprotokolle/ Downloads/KurzProt_Sit-zung73.pdf? blob=publicationFile (accessed on 12-Aug-2015).
    PubMedGoogle Scholar
  • 13 Hewitt PE, Ijaz S, Brailsford SR. et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet 2014; 384: 1766-1773.
    CrossrefPubMedGoogle Scholar
  • 14 Thim L, Vandahl B, Karlsson J. et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia 2010; 16: 349-359.
    CrossrefPubMedGoogle Scholar
  • 15 Reedtz-Runger SL, Lamberth K, Balling KW, Padkjaer SB. Computational analysis indicates different HLA Class II binding properties of peptides from the B domain junctions of different B domain modified FVIII molecules. Haemophilia 2014; 20 (Suppl. 02) 44.
    CrossrefPubMedGoogle Scholar
  • 16 Jeffs S. Expression of recombinant biomedical products from continuous mammalian cell lines. In: Stacey G, Davis J. editors. Medicines from Animal Cell Culture. West Sussex: John Wiley & Sons Ltd; 2007: 61-77.
    Google Scholar
  • 17 Nielsen PF, Bak S, Vandahl B. Characterization of tyrosine sulphation in rFVIII (turoctocog alfa) expressed in CHO and HEK-293 cells. Haemophilia 2012; 18: e397-e398.
    CrossrefPubMedGoogle Scholar
  • 18 Lentz SR, Seremetis S, Staber J, Kulkarni R. Turoctocog alfa and drug development for hemophilia A. Exp Opin Orphan Drugs 2014; 02: 419-431.
    PubMedGoogle Scholar
  • 19 Summary of EPAR for the public. Nuwiq. 2014
    PubMedGoogle Scholar
  • 20 Franchini M, Lippi G. Recombinant factor FVIII concentrates. Semin Thromb Hemost 2010; 36: 493-497.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 General Electric (GE) Healthcare. Strategy for protein purification. 2010
    PubMedGoogle Scholar
  • 22 Kjalke M, Heding A, Talbo G. et al. Amino acid residues 721-729 are required for full factor VIII activity. Eur J Biochem 1995; 234: 773-779.
    CrossrefPubMedGoogle Scholar
  • 23 Newell JL, Fay PJ. Acidic residues C-terminal to the A2 domain facilitate thrombin-catalyzed activation of factor VIII. Biochemistry 2008; 47: 8786-8795.
    CrossrefPubMedGoogle Scholar
  • 24 Ellgaard TW, Bindslev L, Kamstrup S. Viral clearance capacity and robustness of turoctocog alfa manufactoring process. Haemophilia 2015; 21: 14-94.
    CrossrefPubMedGoogle Scholar
  • 25 Nelson DL, Cox MM. Amino acids, peptides, and proteins. Lehninger Principles of Biochemistry. New York: WH Freeman and Co; 2005: 75-115.
    Google Scholar
  • 26 Skands ARH, Kot DEngelund, Rossmeils CC. et al. Stability of turoctocog alfa, a new rFVIII product from Novo Nordisk, when stored at high temperature and humidity. Haemophilia 2014; 20: 176.
    CrossrefPubMedGoogle Scholar
  • 27 Pipe SW. Functional roles of the factor VIII B domain. Haemophilia 2009; 15: 1187-1196.
    CrossrefPubMedGoogle Scholar
  • 28 Furuya K, Murai K, Yokoyama T. et al. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process. Vox Sang 2006; 91: 119-125.
    CrossrefPubMedGoogle Scholar
  • 29 Grancha S, Navajas R, Marañón C. et al. Incomplete tyrosine 1680 sulphation in recombinant FVIII concentrates. Haemophilia 2011; 17: 709-710.
    CrossrefPubMedGoogle Scholar
  • 30 Kannicht C, Ramström M, Kohla G. et al. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thromb Res 2013; 131: 78-88.
    CrossrefPubMedGoogle Scholar
  • 31 Viuff D, Barrowcliffe T, Saugstrup T. et al. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia 2011; 17: 695-702.
    CrossrefPubMedGoogle Scholar
  • 32 Tiede A, Ezban M, Krogh-Melbom TK. et al. Factor VIII assessment using one-stage clot and chromogenic assay in trials investigating pharmakokinetics of different FVIII agents. J Thromb Haemost 2013; 11 (Suppl. 02) 974.
    PubMedGoogle Scholar
  • 33 EMA Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products. 2011
    PubMed
  • 34 Kulkarni R, Karim FA, Glamocanin S. et al. Results from a large multinational clinical trial (guardian3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia 2013; 19: 698-705.
    CrossrefPubMedGoogle Scholar
  • 35 Lentz SR, Misgav M, Ozelo M. et al. Results from a large multinational clinical trial (guardian1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia 2013; 19: 691-697.
    CrossrefPubMedGoogle Scholar
  • 36 Ozelo M, Misgav M, Abdul-Karim F. et al. Reductions in annualized bleeding rates over time with turoctocog alfa prophylaxis: 3-year interim resilts of the guardianTM2 extension trial. Haemophilia. 2014 20. (Suppl 3): 84
    PubMedGoogle Scholar
  • 37 Santagostino E, Lentz SR, Misgav M. et al. Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardianTM clinical trials. Haemophilia 2015; 21: 34-40.
    PubMedGoogle Scholar
  • 38 Santagostino E, Lentz SR, Busk AK. et al. Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. Haemophilia 2014; 20: 527-534.
    CrossrefPubMedGoogle Scholar
  • 39 Novo Nordisk A/S.. Safety and efficacy of turoctocog alfa in prevention and treatment of bleeds in previously untreated children with haemophilia A (guardianTM4). 5-9-2014.
    PubMedGoogle Scholar
  • 40 Novo Nordisk A/S.. Safety and efficacy of turoctocog alfa during long-term treatment of severe and moderately severe haemophilia A (guardianTM5). 5-9-2014.
    PubMedGoogle Scholar
  • 41 Tiede A, Brand B, Fischer R. et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia. J Thromb Haemost 2013; 11: 670-678.
    CrossrefPubMedGoogle Scholar